Indeed, combined therapy with MEK and PI3K-AKT inhibitors has synergistic cytotoxic effects in leukemic cells from pediatric T-ALL patients carrying IL7R signaling mutations [108]. The gene discussed is MAP2K7; the disease is acute lymphoblastic leukemia.